Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xisomab 3G3 for Catheter-Associated Thrombosis
NCT04465760Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Xisomab 3G3 in thrombosis, sponsored by OHSU Knight Cancer Institute. Started Feb 2021; status: terminated.
02
Drugs
Xisomab 3G3
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04465760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465760.